Mitochondrial aldehyde dehydrogenase activity protects against lipopolysaccharide‑induced cardiac dysfunction in rats

Hu,Ying; Yan,Jin‑Bin; Zheng,Ming‑Zhi; Song,Xing‑Hui; Wang,Lin‑Lin; Shen,Yue‑Liang; Chen,Ying‑Ying

doi:10.3892/mmr.2014.2803

Mitochondrial aldehyde dehydrogenase activity protects against lipopolysaccharide‑induced cardiac dysfunction in rats

Authors:
- Ying Hu
- Jin‑Bin Yan
- Ming‑Zhi Zheng
- Xing‑Hui Song
- Lin‑Lin Wang
- Yue‑Liang Shen
- Ying‑Ying Chen
View Affiliations

Affiliations: Department of Ultrasonography, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Department of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China, Department of Pharmacology, Zhejiang Medical College, Hangzhou, Zhejiang 310053, P.R. China
Published online on: October 29, 2014 https://doi.org/10.3892/mmr.2014.2803
Pages: 1509-1515

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myocardial dysfunction in sepsis is associated with an increased risk of mortality. The mitochondrial aldehyde dehydrogenase (ALDH2) enzyme is crucial for protecting the heart from ischemic injury. The aim of the present study was to determine the role of ALDH2 in cardiac dysfunction induced by lipopolysaccharide (LPS). Male rats were treated intraperitoneally with LPS, and their stroke volume and cardiac output were evaluated using an M‑mode echocardiograph. The expression levels and activity of ALDH2, nitric oxide content and inducible nitric oxide synthase (iNOS) activity, and the opening of the mitochondrial permeability transition pore (MPTP) were also evaluated. Treatment with LPS (5, 10, or 20 mg/kg) resulted in a steady decrease in cardiac output and stroke volume. The ALDH2 activity was decreased in a dose‑dependent manner; however, the ALDH2 protein expression levels remained unchanged. Alda‑1, a specific activator of ALDH2, increased the activity of ALDH2 and lessened LPS‑induced cardiac dysfunction. A marked opening of the MPTP was observed 12 h following treatment with LPS, which was prevented by Alda‑1. The improvement in cardiac function in response to treatment with Alda‑1, was partially prevented by treatment with the MPTP inhibitor atractyloside. LPS treatment induced an increase in iNOS activation and inhibition of ALDH2 activity. The iNOS selective inhibitor, aminoguanidine, partially reversed the LPS‑induced ALDH2 activity decrease and MPTP opening. These results indicate that ALDH2 activity may have a role in protecting against LPS‑induced cardiac dysfunction. The potential mechanism may involve inhibition of MPTP opening and iNOS expression.

View Figures

View References

1	Levy MM, Dellinger RP, Townsend SR, et al: The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 36:222–231. 2010. View Article : Google Scholar : PubMed/NCBI
2	Flierl MA, Rittirsch D, Huber-Lang MS, Sarma JV and Ward PA: Molecular events in the cardiomyopathy of sepsis. Mol Med. 14:327–336. 2008.PubMed/NCBI
3	Flynn A, Chokkalingam Mani B and Mather PJ: Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms. Heart Fail Rev. 15:605–611. 2010. View Article : Google Scholar : PubMed/NCBI
4	Khadour FH, Panas D, Ferdinandy P, et al: Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats. Am J Physiol Heart Circ Physiol. 283:H1108–1115. 2002.PubMed/NCBI
5	Revelly JP, Tappy L, Martinez A, et al: Lactate and glucose metabolism in severe sepsis and cardiogenic shock. Critical care medicine. 33:2235–40. 2005. View Article : Google Scholar : PubMed/NCBI
6	Ramana KV, Willis MS, White MD, et al: Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation. 114:1838–46. 2006. View Article : Google Scholar : PubMed/NCBI
7	Luo XJ, Liu B, Ma QL and Peng J: Mitochondrial Aldehyde Dehydrogenase, a Potential Drug Target for Protection of Heart and Brain from Ischemia/Reperfusion Injury. Current drug targets. 15:948–55. 2014.PubMed/NCBI
8	Chen CH, Budas GR, Churchill EN, et al: Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science. 321:1493–1495. 2008. View Article : Google Scholar : PubMed/NCBI
9	Wang J, Wang H, Hao P, et al: Inhibition of aldehyde dehydrogenase 2 by oxidative stress is associated with cardiac dysfunction in diabetic rats. Mol Med. 17:172–179. 2011.
10	Doser TA, Turdi S, Thomas DP, et al: Transgenic overexpression of aldehyde dehydrogenase-2 rescues chronic alcohol intake-induced myocardial hypertrophy and contractile dysfunction. Circulation. 119:1941–1949. 2009. View Article : Google Scholar : PubMed/NCBI
11	Ge W, Guo R and Ren J: AMP-dependent kinase and autophagic flux are involved in aldehyde dehydrogenase-2-induced protection against cardiac toxicity of ethanol. Free Radic Biol Med. 51:1736–1748. 2011. View Article : Google Scholar : PubMed/NCBI
12	Koda K, Salazar-Rodriguez M, Corti F, et al: Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release from cardiac mast cells. Circulation. 122:771–781. 2010. View Article : Google Scholar : PubMed/NCBI
13	Hickson-Bick DL, Jones C and Buja LM: Stimulation of mitochondrial biogenesis and autophagy by lipopolysaccharide in the neonatal rat cardiomyocyte protects against programmed cell death. J Mol Cell Cardiol. 44:411–418. 2008. View Article : Google Scholar
14	Balija TM and Lowry SF: Lipopolysaccharide and sepsis-associated myocardial dysfunction. Curr Opin Infect Dis. 24:248–253. 2011. View Article : Google Scholar : PubMed/NCBI
15	Baines CP, Song CX, Zheng YT, et al: Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res. 92:873–880. 2003. View Article : Google Scholar : PubMed/NCBI
16	Stewart MJ, Malek K and Crabb DW: Distribution of messenger RNAs for aldehyde dehydrogenase 1, aldehyde dehydrogenase 2, and aldehyde dehydrogenase 5 in human tissues. J Investig Med. 44:42–46. 1996.PubMed/NCBI
17	Vasiliou V, Pappa A and Estey T: Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab Rev. 36:279–299. 2004. View Article : Google Scholar : PubMed/NCBI
18	Liao J, Sun A, Xie Y, et al: Aldehyde dehydrogenase-2 deficiency aggravates cardiac dysfunction elicited by endoplasmic reticulum stress induction. Mol Med. 18:785–793. 2012.PubMed/NCBI
19	Zhang P, Xu D, Wang S, et al: Inhibition of aldehyde dehydrogenase 2 activity enhances antimycin-induced rat cardiomyocytes apoptosis through activation of MAPK signaling pathway. Biomed Pharmacother. 65:590–593. 2011. View Article : Google Scholar
20	Ma H, Guo R, Yu L, Zhang Y and Ren J: Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: role of autophagy paradox and toxic aldehyde. Eur Heart J. 32:1025–1038. 2011. View Article : Google Scholar :
21	Zhang Y, Babcock SA, Hu N, et al: Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: role of GSK3β and mitochondrial function. BMC Med. 10:402012. View Article : Google Scholar
22	Baines CP: The cardiac mitochondrion: nexus of stress. Annu Rev Physiol. 72:61–80. 2010. View Article : Google Scholar : PubMed/NCBI
23	Hausenloy DJ, Duchen MR and Yellon DM: Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res. 60:617–625. 2003. View Article : Google Scholar : PubMed/NCBI
24	Hunter DR, Haworth RA and Southard JH: Relationship between configuration, function, and permeability in calcium-treated mitochondria. J Biol Chem. 251:5069–5077. 1976.PubMed/NCBI
25	Halestrap AP: A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection. Biochem Soc Trans. 38:841–860. 2010. View Article : Google Scholar : PubMed/NCBI
26	Ohta S, Ohsawa I, Kamino K, Ando F and Shimokata H: Mitochondrial ALDH2 deficiency as an oxidative stress. Ann NY Acad Sci. 1011:36–44. 2004. View Article : Google Scholar : PubMed/NCBI
27	McDonald LJ and Moss J: Nitric oxide-independent, thiol-associated ADP-ribosylation inactivates aldehyde dehydrogenase. J Biol Chem. 268:17878–17882. 1993.PubMed/NCBI
28	DeMaster EG, Redfern B, Quast BJ, Dahlseid T and Nagasawa HT: Mechanism for the inhibition of aldehyde dehydrogenase by nitric oxide. Alcohol. 14:181–189. 1997. View Article : Google Scholar : PubMed/NCBI
29	Seija M, Baccino C, Nin N, et al: Role of peroxynitrite in sepsis-induced acute kidney injury in an experimental model of sepsis in rats. Shock. 38:403–410. 2012. View Article : Google Scholar : PubMed/NCBI
30	Moon KH, Kim BJ and Song BJ: Inhibition of mitochondrial aldehyde dehydrogenase by nitric oxide-mediated S-nitrosylation. FEBS Lett. 579:6115–6120. 2005. View Article : Google Scholar : PubMed/NCBI